摘要
目的研究妈富隆与米非司酮治疗更年期功能失调性子宫出血(后简称功血)的疗效和安全性。方法选择该院2015年1-9月确诊的更年期功血患者131例,采用隐匿数字随机法分为2组,妈富隆组65例和米非司酮组66例,比较2组治疗前、疗程结束时子宫内膜厚度、雌二醇(E2)、卵泡刺激素(FSH)、黄体生成素(LH)水平;所有患者停药后随访6个月评价疗效,并记录用药期间不良反应。结果 2组治疗后子宫内膜厚度显著低于治疗前,差异有统计学意义(P<0.05)。妈富隆组治疗后子宫内膜厚度显著低于米非司酮组,差异有统计学意义(P<0.05)。妈富隆组治疗后E2、FSH、LH水平较治疗前显著降低,差异有统计学意义(P<0.05)。米非司酮组治疗后E2、FSH、LH水平较治疗前,差异无统计学意义(P>0.05)。妈富隆组治疗后E2、FSH、LH水平显著低于米非司酮组,差异有统计学意义(P<0.05)。妈富隆组总有效率为92.31%,米非司酮组总有效率为83.33%,差异有统计学意义(P<0.05)。妈富隆组复发率为4.62%,米非司酮组复发率为6.06%,差异有统计学意义(P>0.05)。妈富隆组不良反应发生率为9.23%;米非司酮组不良反应发生率为6.06%,差异有统计学意义(P>0.05)。2组患者治疗前后肝肾功能指标、血糖、体质量均无显著变化。结论妈富隆与米非司酮治疗更年期功血安全性基本相同,但妈富隆疗效优于米非司酮。
Objective To investigate the effect and safety of Marvelon and mifepristone in treating peri-menopause dysfunctional uterine bleeding. Methods A total of 131 patients with peri-menopause dysfunctional uterine bleeding in our hospital from January to September 2015 were selected and divided into the Marvelon group（65 cases） and mifepristone group（66 cases） by using the hid- den digital random method. The endometrial thickness and the levels of estradiol（E2）, follicle-stimulating hormone（FSH） and lute- inizing hormone（LH） before and after treatment were compared between the two groups; All patients were followed up for 6 months after drug withdrawal. The curative effects were evaluated andthe adverse reactions were recorded during medication. Re- sults The endometrial thickness after treatment in the two group was significantly lower than that before treatment（P〈0.05） ;the endometrial thickness after treatment in the Marvelon group was obviously lower than that in the mifepristone group, the difference was statistically signifieant（P〈0.05）. The E2, FSH and LH levels after treatment in the Marvelon group were significantly de- creased compared with before treatment,the difference was statistically significant（P〈0.05）. The E2, FSH and LH levels in the mifepristone group had no statistical difference between before and after treatment（P〉0.05）. The E2, FSH and LH levels after treatment in the Marvelon group were significantly lower than those in the mifepristone group, the difference was statistically sig- nificant（P〈0.05）. The total effective rate was 92.310/6 in the Marvelon group and 83.33% in the mifepristone group, the differ- ence was statistically signifieant（P〈0.05）. The recurrence rate was 4.62% in the Marvelon group and 6.06% in the mifepristone group,the difference was statistically significant（P〈0.05）. The incidence rate of adverse reactions was 9.23% in the Marvelon group and 6.06% in the mifepristone group, the difference was statistically significant（P〈0.05）. The hepatorenal function inde- xes, blood glucose and body weight in the two groups had no obvious changes between before and after treatment. Conclusion The safety of Marvelon and mifepristone for treating peri-menopause dysfunctional uterine bleeding is basically same,but the effect of Marvelon is superior to that of mifepristone.
出处
《检验医学与临床》
CAS
2017年第8期1111-1113,1115,共4页
Laboratory Medicine and Clinic
关键词
妈富隆
米非司酮
更年期功血
疗效
安全性
Marvelon
mifepristone
peri-menopause dysfunctional uterine bleeding
curative effect
security
